Hamed Javan MD
Jewish General Hospital
Dr Javan is a medical doctor, completed Master of Experimental Medicine-Oncology program at McGill University, and working as clinical/research at the Jewish General Hospital with Dr Petr Kavan and Dr Gerald Batist. Dr Javan has established a phase II clinical trial for pancreatic cancer. He has a high interest toward investigator-initiated studies, and running new study protocols. Currently, he is preparing new studies in phase II, III and IV for Pancreatic and Colorectal Cancer. His particular research interest is: Pre—operative FOLFIRINOX in pancreatic cancer.
Systemic Cancer Therapy: Pancreatic and Colorectal Cancer – Pre-operative FOLFIRINOX in pancreatic cancer
Pancreatic Cancer is a disease with poor prognosis. In 2017, its 5-year net survival rate is only 8% with only 2% in metastatic setting and it is third common cause of cancer related death. Only less than 20% of cases are eligible for surgery at diagnosis, so we tried to evaluate the role preoperative FOLFIRINOX in potentially curable pancreatic cancer in retrospective study and clinical trial.
EVEN MORE SEMINARS
Stefan Schuster Datar Cancer Genetics Limited
Clinical Utility of Liquid Biopsy in Brain Tumors
Dr. Anna ME Bruynzeel Amsterdam UMC (formerly VUmc)
MR Guided Adaptive Radiation Therapy; three years of clinical experience at VUmc
Dr. Matthew Prime Roche Diagnostics Information Solutions
Personalized healthcare: Leveraging data to improve patient care through clinical decision support in oncology
Professor Hisham Mehanna InHANSE, Institute of Cancer and Genomic Sciences, University of Birmingham
Clinical trials that change patient care and the lessons learnt
Kate Casey The Leeds Gamma Knife Centre
ICON LEKSELL GAMMA KNIFE STEREOTACTIC RADIOSURGERY